Preparation and Properties of Alpha1-Proteinase Inhibitor Concentrate from Human Plasma

Publisher Website
Google Scholar
Abstract
Alpha1-proteinase inhibitor (α1-PI) has been prepared as a concentrate in quantities large enough for clinical testing of its safety and efficacy in the treatment of emphysema and other disorders. The α1-PI was purified from Cohn fraction IV-—I paste by polyethylene glycol precipitation and DEAE-Sepharose chromatography. The methods used in the purification are gentle and the resulting product behaves almost identically to the α1-PI from plasma. The protein has been heat treated (60°C, 10 h) to lower the risk of transmission of plasma-borne diseases. This resulted in some aggregation of the protein, but did not cause the generation of new antigenic sites. Half-life studies in animals showed that the protein behaved normally (catabolic t1/2 of 68 h).